TRINETRA › Sectors › Healthcare
Viyash Scientific Limited (VIYASH) — share price, P/E and fundamentals
Viyash Scientific Limited (NSE: VIYASH) closed at ₹218.39 on 30 Oct 2026, +7.9% over one year, against a 52-week range of ₹178.13 – ₹298.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 11 Aug 2026) it reported revenue of ₹946 cr and net profit of ₹66 cr, a 7.0% net margin; revenue grew 114.4% and profit grew 340.5% year on year.
On four consecutive filed quarters its trailing P/E is 55.7; since 20 May 2025 its own P/E has ranged from 50.8 to 499.8 (median 333.8), and today's reading is higher than 1% of those 358 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 9.1%, ROCE 13.6%, debt-to-equity 0.15, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 16% of 63 sector peers; PBT margin higher than 19% of 63 sector peers; ROE higher than 21% of 63 sector peers.
Key figures
| Last close | ₹218.39 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -11.2% / +5.4% / +7.9% |
| 52-week low – high | ₹178.13 – ₹298.00 |
| Market capitalisation | ₹9,540 cr |
| Trailing P/E | 55.7 |
| Price / book | 3.28 |
| EV / EBITDA | 16.4 |
| Earnings yield | 1.8% |
| TTM EPS | ₹3.92 |
| TTM net profit | ₹171 cr |
| Quarter revenue | ₹946 cr |
| Quarter net profit | ₹66 cr |
| Net margin | 7.0% |
| Revenue growth (YoY) | +114.4% |
| Profit growth (YoY) | +340.5% |
| Return on equity | 9.1% |
| ROCE | 13.6% |
| Debt / equity | 0.15 |
| Current ratio | 2.38 |
| Free cash flow | ₹188 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹60.4 cr |
Against Healthcare peers
| Metric | VIYASH | Peer median | Percentile |
|---|---|---|---|
| Net margin | 6.96 | 12.89 | 16 |
| PBT margin | 11.88 | 17.68 | 19 |
| ROE | 9.05 | 13.87 | 21 |
| ROCE | 13.57 | 17.26 | 33 |
| Debt / equity | 0.15 | 0.11 | 58 |
| Cash conversion | 1.44 | 1.25 | 67 |
| Trailing P/E | 55.74 | 43.07 | 64 |
| P/B | 3.28 | 6.02 | 16 |
Questions
What is the P/E ratio of Viyash Scientific Limited?
Viyash Scientific Limited's trailing P/E is 55.7, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 20 May 2025 its P/E has ranged 50.8–499.8.
What were Viyash Scientific Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Viyash Scientific Limited reported revenue of ₹946 cr and net profit of ₹66 cr (consolidated), filed with the exchange on 11 Aug 2026.
What is Viyash Scientific Limited's ROE?
Return on equity is 9.1% based on the balance sheet dated 31 Mar 2026.
Does Viyash Scientific Limited have debt?
Debt-to-equity is 0.15 on the balance sheet dated 31 Mar 2026.
What is VIYASH's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, VIYASH traded between ₹178.13 and ₹298.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.